87 related articles for article (PubMed ID: 20303840)
21. Complete eradication of hepatitis C virus after interferon treatment for chronic hepatitis C.
De Mitri MS; Morsica G; Chen CH; Mele L; Baccarini P; Chianese R; Piccinini A; Lazzarin A; Pisi E
Ital J Gastroenterol Hepatol; 1997 Jun; 29(3):255-61. PubMed ID: 9646218
[TBL] [Abstract][Full Text] [Related]
22. HCV carriers with persistently normal ALT Levels: not too much healthy, not true patients.
Puoti C
Rom J Gastroenterol; 2004 Dec; 13(4):329-32. PubMed ID: 15624031
[TBL] [Abstract][Full Text] [Related]
23. Viral load in HCV RNA-positive pregnant women.
Paternoster DM; Santarossa C; Grella P; Palù G; Baldo V; Boccagni P; Floreani A
Am J Gastroenterol; 2001 Sep; 96(9):2751-4. PubMed ID: 11569706
[TBL] [Abstract][Full Text] [Related]
24. Chronic infection with hepatitis C virus in patients with elevated or persistently normal serum alanine aminotransferase levels: comparison of hepatic histology and response to interferon therapy.
Shiffman ML; Stewart CA; Hofmann CM; Contos MJ; Luketic VA; Sterling RK; Sanyal AJ
J Infect Dis; 2000 Dec; 182(6):1595-601. PubMed ID: 11069229
[TBL] [Abstract][Full Text] [Related]
25. Serial quantitation of serum core protein and viral RNA of hepatitis C virus after interferon therapy: increase in viral loads in biochemical responders.
Yoshioka K; Aiyama T; Iwata K; Yano M; Okumura A; Ishikawa T; Kakumu S
Am J Gastroenterol; 1997 Aug; 92(8):1305-9. PubMed ID: 9260795
[TBL] [Abstract][Full Text] [Related]
26. Ribavirin/interferon-alpha sequential treatment of recurrent hepatitis C after liver transplantation.
Giostra E; Kullak-Ublick GA; Keller W; Fried R; Vanlemmens C; Kraehenbuhl S; Locher S; Egger HP; Clavien PA; Hadengue A; Mentha G; Morel P; Negro F
Transpl Int; 2004 May; 17(4):169-76. PubMed ID: 15060764
[TBL] [Abstract][Full Text] [Related]
27. Characteristics of hepatitis C virus before and after interferon treatment in patients with ongoing viraemia but sustained biochemical response.
Donadel E; Pontisso P; Ruvoletto MG; Gerotto M; De Salvo G; Chemello L; Casarin C; Alberti A
J Med Virol; 1998 Jan; 54(1):7-11. PubMed ID: 9443103
[TBL] [Abstract][Full Text] [Related]
28. Parameters predicting response to alpha-interferon treatment in chronic hepatitis C.
Glück T; Seelig R; Dette S; Bühring HJ; Renz M; Kwon S; Wiedmann KH; Weber P
Hepatogastroenterology; 1997; 44(14):484-91. PubMed ID: 9164523
[TBL] [Abstract][Full Text] [Related]
29. Hepatitis C infection in Alaska Natives with persistently normal, persistently elevated or fluctuating alanine aminotransferase levels.
Bruce MG; Bruden D; McMahon BJ; Christensen C; Homan C; Sullivan D; Deubner H; Hennessy T; Williams J; Livingston S; Gretch D
Liver Int; 2006 Aug; 26(6):643-9. PubMed ID: 16842319
[TBL] [Abstract][Full Text] [Related]
30. [The virological and histological states of anti-HCV-positive subjects with normal liver biochemical values].
Shindo M; Arai K; Okuno T
Nihon Rinsho; 1995 Sep; 53 Suppl(Pt 1):565-71. PubMed ID: 7563827
[No Abstract] [Full Text] [Related]
31. [Clinical management of asymptomatic HCV carriers].
Nakamura I; Ochiai K; Imawari M
Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):396-9. PubMed ID: 15359829
[No Abstract] [Full Text] [Related]
32. Risk of alanine aminotransferase flare-up among asymptomatic hepatitis C virus RNA carriers: a 10-year follow-up study.
Tsuji K; Yamasaki K; Yamanishi M; Kawakami M; Shirahama S
J Gastroenterol Hepatol; 2001 May; 16(5):536-40. PubMed ID: 11350550
[TBL] [Abstract][Full Text] [Related]
33. Antiviral treatment of HCV carriers with persistently normal ALT levels.
Puoti C; Bellis L; Galossi A; Guarisco R; Nicodemo S; Spilabotti L; Unto OD
Mini Rev Med Chem; 2008 Feb; 8(2):150-2. PubMed ID: 18289098
[TBL] [Abstract][Full Text] [Related]
34. Interferon for hepatitis C.
Puoti C; Magrini A; Stati T; Rossi P; Montagnese F; Resta S
Lancet; 1997 Feb; 349(9049):398-9. PubMed ID: 9033470
[No Abstract] [Full Text] [Related]
35. [Histological features and HLA-DNA types in HCV carriers with persistently normal ALT levels].
Kuzushita N; Hayashi N; Katayama K; Kamada T
Nihon Rinsho; 1995 Sep; 53 Suppl(Pt 1):576-81. PubMed ID: 7563831
[No Abstract] [Full Text] [Related]
36. Analysis of the core region of HCV genome isolated from patients with chronic hepatitis C during intervals of normal ALT concentration.
Arataki K; Nakanishi T; Ohbatake T; Sanada E; Nakayama J; Katayama K; Sasaki F; Moriya T; Kajiyama G
J Gastroenterol; 1996 Feb; 31(1):140-2. PubMed ID: 8808445
[TBL] [Abstract][Full Text] [Related]
37. [Recent progress in the treatment of interferon-resistant hepatitis C].
Kumada M
Nihon Naika Gakkai Zasshi; 1999 Sep; 88(9):1759-62. PubMed ID: 10581760
[No Abstract] [Full Text] [Related]
38. Hepatitis C virus infection and antiviral treatment.
Omata M; Yokosuka O; Hosoda K; Kato N; Ito Y; Ohto M
Gastroenterol Jpn; 1991 Jul; 26 Suppl 3():230-3. PubMed ID: 1715832
[No Abstract] [Full Text] [Related]
39. [Epidemiologic and therapeutic status study of patients with hepatitis C].
Xu M; Shi HY; Cai WP
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2011 Apr; 25(2):135-6. PubMed ID: 21863640
[TBL] [Abstract][Full Text] [Related]
40. Oxidative stress in symptom-free HCV carriers: relation with ALT flare-up.
Vendemiale G; Grattagliano I; Portincasa P; Serviddio G; Palasciamo G; Altomare E
Eur J Clin Invest; 2001 Jan; 31(1):54-63. PubMed ID: 11168439
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
